Traws Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Traws Pharma, Inc. (TRAW), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TRAW insiders buying or selling?
In the last 12 months, Traws Pharma, Inc. insiders reported 1 open-market purchase ($998.2K) and 0 sales ($0) — net buying of $998.2K. Since February 2018, Trabud has recorded 56 Form 4 filings for TRAW: 42 buys ($12.2M) and 14 sells ($1.6M).
Source: SEC EDGAR Form 4
Key Statistics (February 2018 – Apr 29, 2026)
Total Form 4 filings
56
SEC EDGAR
Insider filers
16
Insider buys (42)
$12.2M
Insider sells (14)
$1.6M
Insider sentiment
Net buyingNet insider flow of $10.5M in net buying since February 2018, and $998.2K in net buying over the last 12 months.
Recent TRAW insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Purchase | 597.7K | $1.67 | $998.2K | SEC ↗ |
| Jan 31, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 1.5K | $1.67 | $2.5K | SEC ↗ |
| Jan 24, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 1.5K | $2.02 | $3.0K | SEC ↗ |
| Jan 18, 2022 | Abraham N. Oler | SVP CORP DEV & GEN COUNSEL | Purchase | 1.5K | $2.20 | $3.3K | SEC ↗ |
| Jan 10, 2022 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 1.5K | $2.39 | $3.6K | SEC ↗ |
| Nov 23, 2021 | Abraham N. Oler | SVP CORP DEV & GEN COUNSEL | Purchase | 1.0K | $3.16 | $3.2K | SEC ↗ |
| Sep 29, 2021 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 2.4K | $4.20 | $10.0K | SEC ↗ |
| Sep 29, 2021 | Mark S. Gelder MD | Chief Medical Officer | Purchase | 2.4K | $4.20 | $10.0K | SEC ↗ |
| Sep 28, 2021 | Steven M Fruchtman | President, Chief Executive Off | Purchase | 2.4K | $4.20 | $10.0K | SEC ↗ |
| Sep 28, 2021 | James J Marino | Director | Purchase | 6.0K | $4.20 | $25.0K | SEC ↗ |
| Feb 17, 2021 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 12.0K | $1.00 | $12.0K | SEC ↗ |
| Feb 17, 2021 | Mark Patrick Guerin | Chief Financial Officer | Purchase | 15.0K | $1.00 | $15.0K | SEC ↗ |
| Feb 17, 2021 | Steven M Fruchtman | President, Chief Executive Off | Purchase | 20.0K | $1.00 | $20.0K | SEC ↗ |
| Feb 17, 2021 | James J Marino | Director | Purchase | 25.0K | $1.00 | $25.0K | SEC ↗ |
| Feb 17, 2021 | Mary Teresa Shoemaker | Director | Purchase | 13.0K | $1.00 | $13.0K | SEC ↗ |
| Dec 14, 2020 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 30.0K | $0.32 | $9.6K | SEC ↗ |
| Nov 30, 2020 | Mary Teresa Shoemaker | Director | Purchase | 37.7K | $0.27 | $10.0K | SEC ↗ |
| Nov 30, 2020 | Mark Patrick Guerin | Chief Financial Officer | Purchase | 21.4K | $0.26 | $5.6K | SEC ↗ |
| Nov 30, 2020 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 20.0K | $0.26 | $5.1K | SEC ↗ |
| Nov 30, 2020 | Steven M Fruchtman | President, Chief Executive Off | Purchase | 40.0K | $0.26 | $10.4K | SEC ↗ |
| Nov 27, 2020 | James J Marino | Director | Purchase | 38.8K | $0.26 | $10.0K | SEC ↗ |
| Aug 31, 2020 | Premkumar E Reddy | Director | Sale | 527.9K | $0.27 | $143.9K | SEC ↗ |
| Aug 31, 2020 | Hoffman Michael B | Director | Sale | 184.4K | $0.27 | $50.1K | SEC ↗ |
| May 21, 2020 | Jerome Groopman | Director | Purchase | 10.0K | $0.36 | $3.6K | SEC ↗ |
| May 20, 2020 | Abraham N. Oler | SVP Corp Dev & Gen Counsel | Purchase | 15.0K | $0.37 | $5.5K | SEC ↗ |
Showing the 25 most recent of 56 Form 4 filings for Traws Pharma, Inc..
Most active TRAW insiders
- Abraham N. Oler11 filings
- TYNDALL CAPITAL PARTNERS L P11 filings
- James J Marino7 filings
- Steven M Fruchtman5 filings
- Mark Patrick Guerin4 filings
Ask anything about TRAW insider activity
Use Trabud's AI agent to query Traws Pharma, Inc.'s Form 4 history in plain English — "Show me TRAW CEO purchases this year" or compare it against any other ticker.
Open the AI agentTRAW insider trading FAQ
Are Traws Pharma, Inc. insiders buying or selling?
In the last 12 months, Traws Pharma, Inc. insiders reported 1 open-market purchase ($998.2K) and 0 sales ($0) — net buying of $998.2K. Since February 2018, Trabud has recorded 56 Form 4 filings for TRAW: 42 buys ($12.2M) and 14 sells ($1.6M). Over the full record that is net buying of $10.5M.
How many insiders trade TRAW stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Traws Pharma, Inc.. The most recent filing was accepted on Apr 29, 2026.
Where does Trabud get TRAW insider trading data?
All TRAW insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.